NewsNow: National Institutes of Health news
Read the latest National Institutes of Health headlines, on NewsNow: the one-stop shop for National Institutes of Health news
Source: newsnow.co.uk
Page 12 - Open Label Study News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Open Label Study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Open Label Study Today - Breaking & Trending Today
Ferring Pharmaceuticals: Ferring and Rebiotix to Present Landmark Data for Investigational Microbiota-based Live Biotherapeutic RBX2660 at Digestive Disease Week (DDW) 2021
Ferring Pharmaceuticals: Ferring and Rebiotix to Present Landmark Data for Investigational Microbiota-based Live Biotherapeutic RBX2660 at Digestive Disease Week (DDW) 2021 Clostridioides difficile Infection With and Without Sepsis Presenting Author: Alpesh Amin, MD, MBA, Thomas Mary Cesario Chairman, Department of Medicine, Executive Director, Hospitalist Program, University of California Irvine EMBARGOED UNTIL PRESENTATION TIME: FRIDAY, MAY 21 AT 12:15 PM ET DDW has made abstracts available on their website. About RBX2660 RBX2660 is a potential first-in-class microbiota-based live biothera...
Source: finanznachrichten.de
Cyclo Therapeutics Announces Positive Efficacy Data from Extension Protocol with Trappsol Cyclo in Patients with Niemann-Pick Disease Type C
Posted on 312 Cyclo Therapeutics, Inc. (NasdaqCM:CYTH) (NasdaqCM:CYTHW), a clinical stage biotechnology company developing a cyclodextrin platform for the treatment of neurodegenerative diseases, including its lead candidate Trappsol ® Cyclo™ for the treatment of Niemann-Pick Disease Type C (NPC), today announced initial data from its “Open-Label Study of Long-Term Safety and Efficacy of Intravenous Trappsol ® Cyclo™ (HPBCD) in Niemann-Pick Disease Type C,” NCT03893071. Eight patients living in the US who completed the Ph...
Source: financialbuzz.com